Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer

被引：0
|
作者：
Horiguchi, J. [1 ]
Koibuchi, Y. [1 ]
Rokutanda, N. [1 ]
Nagaoka, R. [1 ]
Kikuchi, M. [1 ]
Sato, A. [1 ]
Ishikawa, Y. [1 ]
Odawara, H. [1 ]
Iino, Y. [1 ]
Takeyoshi, I. [1 ]
机构：
[1] Gunma Univ Hosp, Maebashi, Gunma, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3045
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer.
    Bernardo, G
    Palumbo, R
    Bernardo, A
    Villani, G
    Melazzini, M
    Poggi, G
    Frascaroli, M
    Jedrychowska, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 59S - 59S
  • [43] Updated results of a randomized phase III study of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC): efficacy and safety
    Robert, Nicholas
    Leyland-Jones, Brian
    Asmar, Lina
    Belt, Robert
    Ilegbodu, Des
    Loesch, David
    Raju, Robert
    Cobleigh, Melody
    Albain, Kathy
    Slamon, Dennis
    ANNALS OF ONCOLOGY, 2004, 15 : 39 - 39
  • [44] HER2 down-modulation increases sensitivity to trastuzumab in HER2-overexpressing breast cancer cells
    Valabrega, Giorgio
    Montemurro, Filippo
    Aglietta, Massimo
    Giordano, Silvia
    ANNALS OF ONCOLOGY, 2005, 16 : 30 - 30
  • [45] Lapatinib for the treatment of HER2-overexpressing breast cancer
    Jones, J.
    Takeda, A.
    Picot, J.
    von Keyserlingk, C.
    Clegg, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 1 - 6
  • [46] Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
    Conlin, Alison K.
    Seidman, Andrew D.
    Bach, Ariadne
    Lake, Diana
    Dickler, Maura
    D'Andrea, Gabriella
    Traina, Tiffany
    Danso, Michael
    Brufsky, Adam M.
    Saleh, Mansoor
    Clawson, Alicia
    Hudis, Clifford A.
    CLINICAL BREAST CANCER, 2010, 10 (04) : 281 - 287
  • [47] Longterm survival benefit of neoadjuvant liposomal doxorubicin, docetaxel, and trastuzumab in HER2-overexpressing breast cancer: A retrospective and multicenter analysis.
    Brunner, Christine
    Wieser, Verena
    Jaeger, Thomas
    Lang, Alois
    Stoger, Herbert
    Suppan, Christoph
    Goebel, Georg
    Soleiman, Afschin
    Egle, Daniel
    Marth, Christian
    Hubalek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] SRC INHIBITION OVERCOMES TRASTUZUMAB RESISTANCE IN HER2-OVEREXPRESSING BREAST CANCERS
    不详
    CANCER DISCOVERY, 2011, 1 (01) : 11 - 11
  • [49] Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis
    Brunner, Christine
    Jaeger, Thomas
    Suppan, Christoph
    Mueller-Holzner, Elisabeth
    Jasarevic, Zerina
    Balic, Marija
    Goebel, Georg
    Marth, Christian
    Stoeger, Herbert
    Samonigg, Hellmut
    Hubalek, Michael
    Lang, Alois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
    Burstein, Harold J.
    Keshaviah, Aparna
    Baron, Ari D.
    Hart, Ronald D.
    Lambert-Falls, Rosemary
    Marcom, P. Kelly
    Gelman, Rebecca
    Winer, Eric P.
    CANCER, 2007, 110 (05) : 965 - 972
12345